{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:03:22Z","timestamp":1777608202755,"version":"3.51.4"},"reference-count":30,"publisher":"Oncology Nursing Society (ONS)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2013,2,1]]},"DOI":"10.1188\/13.cjon.34-40","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T21:03:39Z","timestamp":1359666219000},"page":"34-40","source":"Crossref","is-referenced-by-count":12,"title":["Histone Deacetylase Inhibitors"],"prefix":"10.1188","volume":"17","author":[{"given":"Erica","family":"Glass","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela Hallquist","family":"Viale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2013,1,31]]},"reference":[{"key":"1","first-page":"285","article-title":"The molecular mechanism of HDAC inhibitors in anticancer effects","volume":"3","author":"G. Bi","year":"2006","journal-title":"Cellular and Molecular Immunology"},{"key":"2","doi-asserted-by":"publisher","first-page":"7386","DOI":"10.1158\/0008-5472.CAN-04-3433","article-title":"Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors","volume":"65","author":"M. Blagosklonny","year":"2005","journal-title":"Cancer Research"},{"key":"3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1146\/annurev.biochem.73.011303.073651","article-title":"The SIR2 family of protein deacetylases","volume":"73","author":"G. Blander","year":"2004","journal-title":"Annual Review of Biochemistry"},{"key":"4","unstructured":"Celgene Corporation. (2011). <i>Istodax\u00ae (romidepsin)<\/i> [Prescribing information]. Retrieved from <a target=\"_blank\" href='http:\/\/www.istodax.com\/pdfs\/ISTODAX_PackageInsert.pdf'>http:\/\/www.istodax.com\/pdfs\/ISTODAX_PackageInsert.pdf<\/a>"},{"key":"5","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1158\/0008-5472.CAN-06-3996","article-title":"Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation","volume":"67","author":"C. Chen","year":"2007","journal-title":"Cancer Research"},{"key":"6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002","volume":"143","author":"V. Criscione","year":"2007","journal-title":"Archives of Dermatology"},{"key":"7","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/cncr.22252","article-title":"Significant impact of cutaneous T-cell lymphoma on patients' quality of life: Results of a 2005 National Cutaneous Lymphoma Foundation Survey","volume":"107","author":"M. Demierre","year":"2006","journal-title":"Cancer"},{"key":"8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/sj\/onc\/1205108","article-title":"Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling","volume":"21","author":"C. Deroanne","year":"2002","journal-title":"Oncogene"},{"issue":"1","key":"9","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9596-y","article-title":"Histone deacetylase inhibitors: Potential targets responsible for their anti-cancer effect","volume":"28","author":"M. Dickinson","year":"2010","journal-title":"Investigational New Drugs"},{"key":"10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","article-title":"Histone deacetylase inhibitors: Overview and perspectives","volume":"5","author":"M. Dokmanovic","year":"2007","journal-title":"Molecular Cancer Research"},{"key":"11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"M. Duvic","year":"2007","journal-title":"Blood"},{"key":"12","article-title":"Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors","author":"M. Federico","year":"2011","journal-title":"Journal of Biomedicine and Biotechnology"},{"key":"13","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1136\/jcp.2005.029165","article-title":"Expression of HDAC1 and CBP\/p300 in human colorectal carcinomas","volume":"60","author":"K. Ishihama","year":"2007","journal-title":"Journal of Clinical Pathology"},{"key":"14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrd772","article-title":"Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer","volume":"1","author":"R. Johnstone","year":"2002","journal-title":"Nature Reviews Drug Discovery"},{"key":"15","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/jid.2010.8","article-title":"Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes","volume":"130","author":"E. Laharanne","year":"2010","journal-title":"Journal of Investigative Dermatology"},{"key":"16","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"A. Lane","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2165\/11532190-000000000-00000","article-title":"Current and emerging treatment strategies for cutaneous T-cell lymphoma","volume":"70","author":"F. Lansigan","year":"2010","journal-title":"Drugs"},{"key":"18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: Potential in cancer therapy","volume":"107","author":"P. Marks","year":"2009","journal-title":"Journal of Cellular Biochemistry"},{"key":"19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.cnur.2007.07.002","article-title":"Cutaneous T-cell lymphoma: Overview and nursing perspectives","volume":"42","author":"S. McCann","year":"2007","journal-title":"Nursing Clinics of North America"},{"key":"20","unstructured":"Merck & Co., Inc. (2011). <i>Zolinza\u00ae (vorinostat)<\/i> [Prescribing information]. Retrieved from <a target=\"_blank\" href='http:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zolinza\/zolinza_pi.pdf'>http:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zolinza\/zolinza_pi.pdf<\/a>"},{"key":"21","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment-refractory cutaneous T-cell lymphoma","volume":"25","author":"E. Olsen","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"22","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"R. Piekarz","year":"2011","journal-title":"Blood"},{"key":"23","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"R. Piekarz","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/eurheartj\/ehn603","article-title":"Epigenetic histone acetylation modifiers in vascular remodeling: New targets for therapy in cardiovascular disease","volume":"30","author":"D. Pons","year":"2009","journal-title":"European Heart Journal"},{"key":"25","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1158\/0008-5472.CAN-05-3632","article-title":"Rapid alteration of microRNA levels by histone deacetylase inhibition","volume":"66","author":"G. Scott","year":"2006","journal-title":"Cancer Research"},{"key":"26","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-08-2319","article-title":"Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression","volume":"15","author":"J. Suzuki","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1749-6632.2003.tb05964.x","article-title":"Histone deacetylases: Unique players in shaping the epigenetic histone code","volume":"983","author":"S. Thiagalingam","year":"2003","journal-title":"Annals of the New York Academy of Sciences"},{"key":"28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/sj.cdd.4401507","article-title":"Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP","volume":"12","author":"K. Watanabe","year":"2005","journal-title":"Cell Death and Differentiation"},{"key":"29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(08)70004-4","article-title":"Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: A retrospective analysis","volume":"9","author":"W. Weichert","year":"2008","journal-title":"Lancet Oncology"},{"key":"30","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"R. Willemze","year":"2005","journal-title":"Blood"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/837X130400054103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:54:47Z","timestamp":1763754887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/17\/1\/histone-deacetylase-inhibitors"}},"subtitle":["Novel Agents in Cancer Treatment"],"short-title":[],"issued":{"date-parts":[[2013,1,31]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2,1]]}},"alternative-id":["837X130400054103"],"URL":"https:\/\/doi.org\/10.1188\/13.cjon.34-40","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,31]]}}}